News36 seconds ago
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma
SHANGHAI, June 4, 2023 /PRNewswire/ — This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in...
